Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis

Postigo, Ricardo; Kim, J. H.

doi:10.1007/s15010-012-0307-9

Cited by 110 publications

(99 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Factors that might influence the composition of the donor sample include diet, antibiotics/probiotics and a range of environmental exposures, as West 18 well as underlying disease status 94 . From a practical, clinical perspective the route of administration is important and at least for the treatment of C. difficile, colonoscopic and nasogastric administration appears similarly effective 97 , although a higher stool volume was used for FMT in the colonoscopy group. Notably, standardized partially purified and frozen fecal microbiota might be just as effective as the current fresh harvest approach 98 , which might facilitate its clinical use.…”

Section: Fecal Microbiota Transplantationmentioning

confidence: 99%

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

West

Renz²,

Jenmalm

et al. 2015

Journal of Allergy and Clinical Immunology

218

165

View full text Add to dashboard Cite

Rapid environmental transition and modern lifestyles are likely driving changes in the biodiversity of the human gut microbiota. With clear effects on physiologic, immunologic, and metabolic processes in human health, aberrations in the gut microbiome and intestinal homeostasis have the capacity for multisystem effects. Changes in microbial composition are implicated in the increasing propensity for a broad range of inflammatory diseases, such as allergic disease, asthma, inflammatory bowel disease (IBD), obesity, and associated noncommunicable diseases (NCDs). There are also suggestive implications for neurodevelopment and mental health. These diverse multisystem influences have sparked interest in strategies that might favorably modulate the gut microbiota to reduce the risk of many NCDs. For example, specific prebiotics promote favorable intestinal colonization, and their fermented products have anti-inflammatory properties. Specific probiotics also have immunomodulatory and metabolic effects. However, when evaluated in clinical trials, the effects are variable, preliminary, or limited in magnitude. Fecal microbiota transplantation is another emerging therapy that regulates inflammation in experimental models. In human subjects it has been successfully used in cases of Clostridium difficile infection and IBD, although controlled trials are lacking for IBD. Here we discuss relationships between gut colonization and inflammatory NCDs and gut microbiota modulation strategies for their treatment and prevention

show abstract

Section: Fecal Microbiota Transplantationmentioning

confidence: 99%

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

West

Renz²,

Jenmalm

et al. 2015

Journal of Allergy and Clinical Immunology

218

165

View full text Add to dashboard Cite

show abstract

“…Various methods of installation are used for FMT which include upper tract endoscopy, nasogastric tube retention enema, colonoscopy and a nasojejunal tube (Gough et al 2011;Postigo and Kim 2012). Nevertheless, it has been suggested that the best route for administration should be determined based on the anatomic location of the disease (Smits et al 2013).…”

Section: Fecal Microbial Therapymentioning

confidence: 99%

The art of targeting gut microbiota for tackling human obesity

Aguirre

Venema

2015

Genes Nutr

View full text Add to dashboard Cite

Recently, a great deal of interest has been expressed regarding strategies to tackle worldwide obesity because of its accelerated wide spread accompanied with numerous negative effects on health and high costs. Obesity has been traditionally associated with an imbalance in energy consumed when compared to energy expenditure. However, growing evidence suggests a less simplistic event in which gut microbiota plays a key role. Obesity, in terms of microbiota, is a complicated disequilibrium that presents many unclear complications. Despite this, there is special interest in characterizing compositionally and functionally the obese gut microbiota with the help of in vitro, animal and human studies. Considering the gut microbiota as a factor contributing to human obesity represents a tool of great therapeutic potential. This paper reviews the use of antimicrobials, probiotics, fecal microbial therapy, prebiotics and diet to manipulate obesity through the human gut microbiota and reveals inconsistencies and implications for future study.

show abstract

“…From a practical, clinical perspective the route of administration is important and at least for the treatment of C. difficile, colonoscopic and nasogastric administration appears similarly effective 97 , although a higher stool volume was used for FMT in the colonoscopy group. Notably, standardized partially purified and frozen fecal microbiota might be just as effective as the current fresh harvest approach 98 , which might facilitate its clinical use.…”

Section: West 18mentioning

confidence: 99%

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

2015

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis

Abstract: Despite procedural differences, FMT via colonoscopy or NGT appears to be highly effective and safe for the management of recurrent CDI.

Cited by 110 publications

References 31 publications

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

The art of targeting gut microbiota for tackling human obesity

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

Contact Info

Product

Resources

About